(zavegepant)

Prescribing Information
Download Prescribing Information

Health Professional Information

Highlights

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ZAVZPRET safely and effectively. See full prescribing information for ZAVZPRET.
 
ZAVZPRET™ (zavegepant) nasal spray
Initial U.S. Approval: 2023

RECENT MAJOR CHANGES

Warnings and Precautions (5.2, 5.3)

3/2025

INDICATIONS AND USAGE

ZAVZPRET is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. (1)

 

Limitations of Use

ZAVZPRET is not indicated for the preventive treatment of migraine. (1)

DOSAGE AND ADMINISTRATION

•
The recommended dose is 10 mg given as a single spray in one nostril, as needed. (2.1)
•
The maximum dose in a 24-hour period is 10 mg (one spray). (2.1)
•
The safety of treating more than 8 migraines in a 30-day period has not been established. (2.1)

DOSAGE FORMS AND STRENGTHS

Nasal spray: 10 mg (3)

CONTRAINDICATIONS

Patients with a history of hypersensitivity reaction to zavegepant or to any of the components of ZAVZPRET. (4)

WARNINGS AND PRECAUTIONS

•
Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue ZAVZPRET and initiate appropriate therapy. Hypersensitivity Reactions including facial swelling and urticaria have occurred with ZAVZPRET. (5.1)
•
Hypertension: New-onset or worsening of pre-existing hypertension may occur. (5.2)
•
Raynaud’s Phenomenon: New-onset or worsening of pre-existing Raynaud’s phenomenon may occur. (5.3)

ADVERSE REACTIONS

Most common adverse reactions (at least 2% of patients treated with ZAVZPRET and greater than placebo) were taste disorders, nausea, nasal discomfort, and vomiting. (6.1)
 

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

•
Avoid use with drugs that inhibit OATP1B3 or NTCP transporters. (7.1)
•
Avoid use with drugs that induce OATP1B3 or NTCP transporters. (7.2)
•
Avoid use of intranasal decongestants; if unavoidable, administer intranasal decongestants at least 1 hour after ZAVZPRET administration. (7.3)

USE IN SPECIFIC POPULATIONS

•
Avoid use in patients with severe hepatic impairment. (8.6)
•
Avoid use in patients with CLcr < 30 mL/min. (8.7)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 3/2025

Medication Guide
Download Consumer Medicine Information

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Additional Resources

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine or vaccine.

Speak with a Pfizer Medical Information Professional regarding your Pfizer medicine or vaccine inquiry.

Available 9AM-5PM ET Monday to Friday; excluding holidays.

 

Submit a medical question for a Pfizer medicine or a vaccine. 

The submission will be reviewed during our standard business hours.

To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this medication, click the link below to submit your information: 
Pfizer Safety Reporting Site

*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.

If you cannot use the above website to report an adverse event related to a Pfizer medication, please call (800) 438-1985.

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or by calling (800) 332-1088.